Drug Development

Regulatory clearances and approvals continue as agencies work to disseminate literature, raise awareness, redouble research efforts, and improve the efficacy of clinical trials.

Webinar Date/Time: Fri, Mar 21, 2025 11:00 AM EDT

While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.

The value of outsourcing partnerships for next-gen biotherapeutics rests in the expertise and technologies that service providers bring to the table.

Webinar Date/Time: Thu, Mar 13, 2025 11:00 AM EDT

The collaboration will utilize Genesis’ proprietary AI platform, initially focusing on targets selected by Incyte.

A capsule formulation may offer more consistent and reliable uptake versus a syringe, while being less dependent on food intake.

The AI co-scientist is a multi-agent AI system that can work as a virtual scientific collaborator.

Pharmaceutical Technology® chatted with Preeya Beczek, managing director and co-founder of Beczek.COM, about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.

Benjamin McLeod, Abhi Naravane, PhD, MBA, and Marianna Tcherpakov PhD go behind the headlines to talk about the latest big acquisitions, GLP-1 Super Bowl advertising, and changes in NIH funding.

The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.

Agnes Cwienczek, director of Product Management at ArisGlobal, talks with Pharmaceutical Technology® about how careers for women in STEM fields can be nurtured.

Pharmaceutical Technology® spoke with Sabine Gölden, eLearning & Training Lead at MAIN5, about her experience working in the pharmaceutical industry.

In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

Investing in STEM programs for girls in an education setting and then supporting women as they excel in their professional careers is key to ensuring that vital highly skilled personnel are not left behind.

Pharmaceutical Technology® sat down with Jean Redmond, Chief Operating Officer at Biologit, to discuss the use of artificial intelligence in pharmaceutical research and development and the role women play in this fast-developing area.

Christian Morello, vice president and head of the Bioconjugates Business Unit at Lonza, looks at what is involved in developing modern ADCs.

While this approval addresses breast cancer, olaparib in combination with durvalumab was approved by the EU in August 2024 for treatment of endometrial cancer.

Feb. 11, 2025 marks the 10th anniversary of the International Day of Women and Girls in Science.

Application of AI/ML technology and a burst of M&A activity look to be shaping the future of the pharma industry.

Pharmaceutical Technology® sat down with Kate Coleman from Arriello to run through the major trends from 2024, including the importance of technological advances, and how these may progress in 2025.

European biopharma companies are looking beyond GLP-1s.

In this interview, Pharmaceutical Technology® discusses the trend of AI in pharma and how it may play out in 2025 and beyond with Ben Sidders from Biorelate.

Increasing API and formulation complexity and new delivery strategies are driving innovations in taste-masking.

Hood, a pioneer of systems biology and systems medicine, shared his personal interest in starting a new peptide-based, informational-driven pharmaceutical company that would address wellness and longevity.

Webinar Date/Time: Tues, March 4, 2025 11:00 AM EST

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.

The tariffs President Trump wants to levy against Canada and Mexico are on hold, for now, but China has already announced it intends to proceed with retaliatory tariffs against the US.

CDMOs who have integrated technologies can help further the advancement of ADC development.

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.